Viriom

About:

Viriom is a clinical and commercial stage biotech developing drugs for treatment, prevention and cure of HIV and other infections.

Website: http://viriom.com/

Twitter/X: viriominc

Top Investors: Torrey Pines Investment, Skolkovo Foundation, ChemRar Ltd, Pharmstandard, MIT RF

Description:

Viriom Inc. is a development and commercial stage biotech company developing novel and affordable medicines against life threatening infections such as HIV and HBV. The company has an exclusive worldwide license to its phase 3 and commercial stage lead compounds (Elpida/elsulfavirine and VM1500A) from Hoffmann-La Roche and has developed proprietary drug candidates VM2500, VM3500 LAI formulations and combinations with cell, vaccine and antibody drugs for treatment, prophylaxis and cure of HIV. Viriom makes a breakthrough in treating, preventing and curing HIV and chronic HBV infections worldwide.

Total Funding Amount:

$35.4M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

San Diego, California, United States

Founded Date:

2009-01-01

Contact Email:

viriom(AT)viriom.com

Founders:

Number of Employees:

251-500

Last Funding Date:

2017-12-06

IPO Status:

Private

Industries:

© 2025 bioDAO.ai